New York, NY -- (SBWIRE) -- 12/20/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Hudson City Bancorp, Inc (NASDAQ:HCBK), Banco Santander, S.A. (ADR) (NYSE:SAN), CEL-SCI Corporation (NYSEMKT:CVM)
Hudson City Bancorp, Inc (NASDAQ:HCBK) showed a volume of 6.63 million shares by the end of last trade whereas the average volume of the stock remained 4.52 million shares. The stock opened the session at $9.19 but then moved to $9.14. At that price, the stock showed a negative performance of -0.76%. Hudson City Bancorp, Inc. (Hudson City Bancorp) serves as the holding company of its subsidiary, Hudson City Savings Bank (the Bank). The Bank is a federal stock savings bank. The Company is a community- and consumer-oriented retail savings bank offering traditional deposit products, residential real estate mortgage loans and consumer loans. In addition, it purchases mortgages and mortgage-
Will HCBK Get Buyers Even After The Recent Rally? Find Out Here
Banco Santander, S.A. (ADR) (NYSE:SAN) the stock advanced 0.81% and finished the session at $8.69. Traded with volume of 5.98 million shares in the prior session and the average volume of the stock remained 5.57 million shares. The beta of the stock remained 1.93. Banco Santander SA is a Spain-based commercial bank. The Bank operates principally in Spain, the United Kingdom, Portugal, the Latin American countries and the United States. It operates four segments: Continental Europe, the United Kingdom, Latin America and Sovereign. Continental Europe segment covers all retail banking business, wholesale banking and asset management and insurance conducted in Europe, under such names as Santander Totta, Santander Consumer Bank and Bank Zachodni WBK, among others.
Will SAN Continue To Move Higher? Find Out Here
CEL-SCI Corporation (NYSEMKT:CVM) opened the session at $0.58 and closed the session at $0.568. The stock showed a negative performance of -20.03% in previous trading session. Traded with volume of 2.39 million shares in the prior session and the average volume of the stock remained 457,397.00 shares. The beta of the stock remained 2.15. CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
Why Should Investors Buy CVM After the Recent Fall? Just Go Here and Find Out
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)